Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report
Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report
复制标题
索磷布韦联合利巴韦林的无干扰素治疗成功治疗基因型 2 型丙型肝炎病毒合并扁平苔藓：病例报告
DOI：
10.1007/s12328-017-0742-3
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Sakamoto Naoya
中科院分区：
文献类型：
--
作者：
Yoshikawa Ayumu;Terashita Katsumi;Morikawa Kenichi;Matsuda Soichiro;Yamamura Takahiro;Sarashina Koichiro;Nakano Shintaro;Kobayashi Yoshimitsu;Sogabe Susumu;Takahashi Kazuhiro;Haba Shin;Oda Hisashi;Takahashi Tatsuro;Miyagishima Takuto;Sakamoto Naoya
丙型肝炎病毒（HCV）感染仍然是肝脏疾病的主要原因，可导致慢性肝炎、肝硬化和肝细胞癌。HCV也可能在皮肤、眼睛、关节、肾脏、神经系统和免疫系统中发展肝外表现。事实上，一些研究报告称，高达70%的HCV患者经历了肝外表现。扁平苔藓（LP）是一种由病毒感染，过敏原和压力引发的免疫系统疾病，可影响皮肤，口腔，指甲和头皮。LP与HCV的相关性已有报道，但HCV治疗对LP缓解的影响存在争议。我们遇到了一个53岁的男子与丙型肝炎病毒基因型2a和LP，成功地与索非布韦和利巴韦林治疗12周。治疗后，他取得了持续的病毒学反应，对丙型肝炎病毒和缓解糜烂LP病变的嘴唇。在以干扰素（IFN）为基础的HCV治疗时代，自身免疫性疾病的恶化是常见的不良事件。因此，使用无干扰素的直接作用抗病毒药物治疗丙型肝炎病毒可能会预防免疫疾病的肝外表现。
Hepatitis C virus (HCV) infection remains the main cause of liver disease and can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV may also develop extrahepatic manifestations in the skin, eyes, joints, kidneys, nervous system, and immune system. In fact, several studies reported that up to 70% of HCV patients experienced extrahepatic manifestations. Lichen planus (LP), which is an immune system disorder that is triggered by viral infections, allergens, and stress, can affect the skin, mouth, nails, and scalp. The association of LP with HCV has been reported, but the effect of HCV treatment on LP remission is controversial. We encountered a 53-year-old man with HCV genotype 2a and LP that were successfully treated with sofosbuvir and ribavirin for 12 weeks. After treatment, he achieved sustained virological response against HCV and remission of erosive LP lesions on the lip. In the era of interferon (IFN)-based treatment for HCV, exacerbation of autoimmune diseases is a common adverse event. Therefore, use of an IFN-free regimen of direct-acting antivirals for HCV might prevent the extrahepatic manifestation of an immune disorder.